Response to induction chemotherapy as predictive marker of tumor response to radiotherapy and survival in oral cavity cancer

Saini, Surendra Kumar; Srivastava, Shelly; Prasad, S N

doi:10.4103/2278-0513.158538

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…is is similar to a study done by Saini SK et al, who showed that response to induction chemotherapy can be a predictive marker for response to subsequent chemoradiotherapy and survival. eir study showed a hazard ratio of 0.463 for mortality in patients achieving partial response or more when compared to others with stable or progressive disease [18].…”

Section: Discussionmentioning

confidence: 93%

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Koramati

Sarathy

Varayathu

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. Induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by definitive concurrent chemoradiation remains the standard of care in locally advanced squamous cell carcinoma of head and neck cancers despite which the survival remains low. So, we analyzed the efficacy and adverse effect profile of the addition of nimotuzumab to standard TPF induction chemotherapy. Methods. We included 20 patients with locally advanced squamous cell carcinoma of the head and neck. Patients were administered with induction chemotherapy with nimotuzumab plus docetaxel, cisplatin, and 5-fluorouracil (TPF + N) followed by definitive concurrent chemoradiation with carboplatin. Treatment responses were assessed by PET-CT following induction chemotherapy and concurrent chemoradiation. Response rates, survival, and adverse effects data were tabulated and analyzed using the Kaplan Meier method. Results. At a minimum follow-up of two years, the median progression-free survival (PFS) and median overall survival (OS) were 16 months and 38 months, respectively. PFS and OS were not reached (NR) in patients who showed a complete radiological response (CR). Median PFS and OS in patients who had partial response were 17.6 and 34.5 months, respectively. All subsites of primary including oral cavity, hypopharynx, and oropharynx showed similar response rates and survival. Overall the treatment was well tolerated with predominantly grade 1/2 toxicities. Conclusions. Patients with locally advanced head and neck cancer could possibly have a better response and survival with nimotuzumab added to the standard TPF regimen. A complete response may serve as a good surrogate for survival irrespective of the primary site of head and neck cancer.

show abstract

Section: Discussionmentioning

confidence: 93%

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Koramati

Sarathy

Varayathu

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…24,25 Another reason for attractiveness towards ICT could be the fact that patients whose tumours responded to CT had good response to subsequent RT. 26,27 ICT seems to be a promising approach in certain clinical scenarios such as laryngeal preservation, unfavourable sites and T3 / T4 or N2 / N3 disease. [28][29][30] Other authors have limited its use to patients with good general condition including performance status 0 or 1, weight loss d" 10%, absence of severe comorbidities, < 70 years of age.…”

Section: Role Of Ict In Present Scenariomentioning

confidence: 99%

The changing landscape of induction chemotherapy in head and neck cancers

Negi¹,

Srivastava²,

Pa³

2019

International Journal of Health Research and Medico Legal Practice

View full text Add to dashboard Cite

In an attempt to improve the survival in locally advanced head and neck carcinomas, varying sequencing of treatment modalities namely surgery, radiation therapy and chemotherapy has been tried. Although concurrent chemoradiotherapy is the standard of care for these patients, induction chemotherapy is considered an effective alternative approach by head and neck oncologists worldwide. Induction chemotherapy continues to be actively pursued because of its potential to control locoregional disease, possible eradication of micrometastasis and organ preservation without jeopardizing overall survival. Inspite of the positive impact of docetaxel-based induction regimens, its direct comparison with the standard treatment failed to show superior results in terms of survival and completion of planned definitive radiation treatment. Several clinical trials have served to clarify the role of induction chemotherapy before definitive treatment in head and neck cancer, still the data remains controversial and warrants randomized controlled trials to ensure that most effective therapy is delivered with subsequent improvement in survival for these patients. This review summarizes key milestones in the evolution of induction chemotherapy in head and neck carcinoma.

show abstract

Response to induction chemotherapy as predictive marker of tumor response to radiotherapy and survival in oral cavity cancer

Cited by 2 publications

References 1 publication

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study

The changing landscape of induction chemotherapy in head and neck cancers

Contact Info

Product

Resources

About